The Industry Innovation Award recognizes a significant proteomics technology advance developed within private industry. This award honors an individual or team for an innovation, such as an instrument, hardware component, workflow, software, reagent or proteomics-based diagnostic or therapy that has been commercialized or otherwise translated into practice. The advance should have been commercially introduced within the previous five years.

The award emphasizes innovations with demonstrated market or field use, technical uniqueness, and broad scientific or societal impact. Nominations may highlight disruptive technologies that address unmet needs or expand the boundaries of proteomics research.

Eligibility

• Nominee(s): An individual or team from a private company/industry organization.
• US HUPO Connection: Eligible companies must be current US HUPO sponsors (corporate members) or have at least one US HUPO member in their group.
• Scope of Innovation: Innovation must be proteomics-focused and demonstrate clear impact.
• Conference Participation: Awardee(s) must attend the annual US HUPO conference (March 6-10, 2027 in Albuquerque, NM) to accept the award and present the innovation.

Award nominations are closed for 2026 and will open for 2027 on March 1, 2026.